Steadybase.

CapsoVision, Inc.

Website Investor relations LinkedIn Latest 10-K
  • CV · Nasdaq
  • Electromedical & Electrotherapeutic Apparatus
  • Saratoga, CA
  • 99 employees
  • CIK 0001378325

Updated from SEC filings through

Top things to know

Revenue, FY2025$13.6M+15.3% vs FY2024Operating margin-188.3%Operating income -$25.5MEmployees99As of December 31, 2025Next earningsNovember 12, 202616:30 ETLatest 8-KOther eventsFiled September 28, 2026

Executives

  • David Michael Garcia David Michael Garcia Sr. VP of Finance 4, 2026-06-03
  • Douglas Patrick Atkinson Head of Global Sales 4, 2026-06-03
  • David Garcia David Garcia Senior VP of Finance (Principal Financial Officer and Principal Accounting Officer) 10-K, 2026-03-26

What leadership is saying

“The second quarter marked another important step in the evolution of CapsoVision as we advanced both our commercial execution and product innovation. We were pleased to launch AI Highlights™ internationally, providing physicians in Europe with an AI-assisted workflow solution that complements our CapsoCam Plus® platform and reinforces our long-term vision of integrated, AI-enabled capsule endoscopy”

Johnny Wang, President and Chief Executive Officer of CapsoVision
Earnings press release (8-K Ex. 99.1), filed August 13, 2026

CapsoVision, Inc is a U.S. public company in electromedical & electrotherapeutic apparatus (SIC 3845), headquartered in Saratoga, CA. It trades as CV on Nasdaq. Revenue was $13.6M in the fiscal year ending December 31, 2025, +15.3% from the year before. It reported about 99 employees. Kang-Huai (Johnny) Wang is Director, President and Chief Executive Officer (Principal Executive Officer).

Five-year financials

MetricFY2025FY2024
Revenue $13.6M
10-K, 2026-03-26 		$11.8M
10-K, 2026-03-26
Operating income -$25.5M
10-K, 2026-03-26 		-$19.9M
10-K, 2026-03-26
SG&A $14.4M
10-K, 2026-03-26 		$11.2M
10-K, 2026-03-26
Net income -$25.3M
10-K, 2026-03-26 		-$19.9M
10-K, 2026-03-26

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Kang-Huai (Johnny) Wang Kang-Huai (Johnny) Wang Director, President and Chief Executive Officer (Principal Executive Officer) 10-K, 2026-03-26
David Michael Garcia David Michael Garcia Sr. VP of Finance 4, 2026-06-03
Douglas Patrick Atkinson Head of Global Sales 4, 2026-06-03
David Garcia David Garcia Senior VP of Finance (Principal Financial Officer and Principal Accounting Officer) 10-K, 2026-03-26
Chen Lung Tsai Chairman of the Board of Directors 10-K, 2026-03-26
Hui Ying (Patty) Kuo Director 10-K, 2026-03-26
Joanne Imperial, M.D. Director 10-K, 2026-03-26
Julia Gouw Director 10-K, 2026-03-26
Keri Jorgenson Director of Clinical Operations 10-K, 2026-03-26
Michele Harari Director 10-K, 2026-03-26
Wen-Herng (Henry) King Director 10-K, 2026-03-26

What CapsoVision, Inc does

We are a global commercial-stage medical technology company focused on creating diagnostic and screening products to identify abnormalities of the GI tract. We develop advanced imaging and AI technologies in creating such products while maximizing the flexibility, convenience, profitability, and safety of patient care. We are a Delaware company, incorporated in 2005. Our corporate headquarters is located in Saratoga, California.

Item 1. Business, 10-K for the year ending December 31, 2025

Shares and governance

Shares outstanding 50.0 million (as of August 12, 2026) 10-Q, August 13, 2026
Public float $0 (as of June 30, 2025) 10-K, March 26, 2026
Reportable segments 1 (period ending June 30, 2026) 10-Q, August 13, 2026
Latest proxy statement Meeting December 31, 2025 (filed April 28, 2026) DEF 14A, April 28, 2026
Auditor Baker Tilly US, LLP (Santa Clara, California) Latest 10-K

Recent 8-K events

  • 8-K filed 2026-09-28
    • Item 8.01 Other events
  • 8-K filed 2026-09-18
    • Item 1.01 Entry into a material definitive agreement
  • 8-K filed 2026-08-18
    • Item 8.01 Other events
  • 8-K filed 2026-08-13
    • Item 1.01 Entry into a material definitive agreement
    • Item 2.02 Results of operations and financial condition (earnings release)
  • 8-K filed 2026-07-02
    • Item 5.02 Departure or appointment of directors or officers; compensation
    • Item 7.01 Regulation FD disclosure
  • 8-K filed 2026-06-12
    • Item 5.07 Submission of matters to a vote of security holders
  • 8-K filed 2026-05-14
    • Item 2.02 Results of operations and financial condition (earnings release)
  • 8-K filed 2026-03-26
    • Item 2.02 Results of operations and financial condition (earnings release)
  • 8-K filed 2026-03-20
    • Item 1.01 Entry into a material definitive agreement
    • Item 2.02 Results of operations and financial condition (earnings release)
    • Item 3.02 Unregistered sales of equity securities
    • Item 7.01 Regulation FD disclosure
    • Item 8.01 Other events
  • 8-K filed 2026-03-13
    • Item 1.01 Entry into a material definitive agreement

Frequently asked questions about CapsoVision, Inc

What does CapsoVision, Inc do?
In its own words, from Item 1 of its 10-K: "We are a global commercial-stage medical technology company focused on creating diagnostic and screening products to identify abnormalities of the GI tract. We develop advanced imaging and AI technologies in creating such products while maximizing the flexibility, convenience, profitability, and safety of patient care. We are a Delaware company, incorporated in 2005. Our corporate headquarters is located in Saratoga, California."
What is CapsoVision, Inc's revenue?
$13.6M for the fiscal year ending December 31, 2025, from its 10-K filed March 26, 2026.
Is CapsoVision, Inc profitable?
CapsoVision, Inc reported net income of -$25.3M for the fiscal year ending December 31, 2025.
How many employees does CapsoVision, Inc have?
About 99 as of December 31, 2025, as stated in its annual report.
Who is the CEO of CapsoVision, Inc?
Kang-Huai (Johnny) Wang, Director, President and Chief Executive Officer (Principal Executive Officer), as named in a 10-K filed March 26, 2026.
Where is CapsoVision, Inc headquartered?
Saratoga, CA.
What is CapsoVision, Inc's stock ticker?
CV on Nasdaq.
What industry is CapsoVision, Inc in?
Electromedical & Electrotherapeutic Apparatus, SIC code 3845.
What is CapsoVision, Inc's website?
capsovision.com. Investor relations: https://investors.capsovision.com/.
When does CapsoVision, Inc report earnings next?
November 12, 2026 at 16:30. Source: pg_future_events.
Is CapsoVision, Inc a public company?
Yes. CapsoVision, Inc files with the SEC under CIK 0001378325 and trades as CV.
Who audits CapsoVision, Inc?
Baker Tilly US, LLP, Santa Clara, California, as named in its latest annual report (10-K).
How many shares of CapsoVision, Inc are outstanding?
50.0 million shares as of August 12, 2026, from its 10-Q filed August 13, 2026.
What is CapsoVision, Inc's public float?
$0 as of June 30, 2025, as reported on the cover of its 10-K filed March 26, 2026.
How many business segments does CapsoVision, Inc report?
1 reportable segment for the period ending June 30, 2026, from its 10-Q filed August 13, 2026.
When is CapsoVision, Inc's annual shareholder meeting?
December 31, 2025, per its proxy statement (DEF 14A) filed April 28, 2026.